Anastasiya Sviridova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anastasiya Sviridova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Mikhail Melnikov
Department of Neuroimmunology, Institute of Clinical Neurology, Federal Center of Brain and Neurotechnologies, FMBA of Russia
10 shared publications - Аleksey N. Boyko
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
7 shared publications - A. V. Lopatina
Federal Center of Brain Research and Neurotechnologies of the Federal Medical and Biological Agency of Russia
5 shared publications - Vladimir Stanislavovich Rogovskii
Department of Neuroimmunology, Institute of Clinical Neurology, Federal Center of Brain and Neurotechnologies, FMBA of Russia
4 shared publications - Anastasia Romanovna Kabaeva
Federal Center for Brain and Neurotechnologies, Federal Medical and Biological Agency of Russia
2 shared publications - D. A. Chugunov
Pirogov Russian National Research Medical University
2 shared publications
Latest Publications
- 14 May 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 89-95
Effect of aripiprazole on cytokine production by T cells in schizophrenia
Objective. To evaluate the modulatory effect of the antipsychotic agent aripiprazole on ex vivo production of the cytokines interleukin-17 (IL-17) and interferon-γ (IFN-γ) by T-lymphocytes in patients with schizophrenia. Material and methods. The study included 15 patients diagnosed with schizophrenia and 12 healthy donors as the control group. A peripheral blood mononuclear cell (PBMC) model was employed to assess the effects of aripiprazole on cytokine profiles. Cells were stimulated with microparticles coated with antibodies to CD3 and CD28 surface markers. To investigate the roles of D1 and D2 dopamine receptors (D1DR and D2DR) in the mechanism of action of aripiprazole, PBMCs were stimulated in the presence of aripiprazole alone and in combination with specific antagonists: SCH23390 for D1DR and sulpiride for D2DR. Concentrations of IL-17 and IFN-γ in culture supernatants were measured using an enzyme-linked immunosorbent assay. Results. In patients with schizophrenia, the induced production of both IL-17 and IFN-γ by PBMC was significantly lower than in the healthy donor group. Aripiprazole exhibited a dose-dependent suppressive effect on cytokine secretion in both groups. Blockade of D1DR enhanced the inhibitory effect of aripiprazole, whereas blockade of D2DR diminished it. Isolated blockade of D1DR, in the absence of aripiprazole, inhibited cytokine production by stimulated PBMCs in both groups, while isolated blockade of D2DR had no significant effect. Conclusion. Aripiprazole may exert anti-inflammatory effects in schizophrenia by inhibiting the secretion of pro-inflammatory cytokines by T cells. This effect is likely mediated through D2DR activation.
- 14 May 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (4) , 89-95
Effect of aripiprazole on cytokine production by T cells in schizophrenia
Objective. To evaluate the modulatory effect of the antipsychotic agent aripiprazole on ex vivo production of the cytokines interleukin-17 (IL-17) and interferon-γ (IFN-γ) by T-lymphocytes in patients with schizophrenia. Material and methods. The study included 15 patients diagnosed with schizophrenia and 12 healthy donors as the control group. A peripheral blood mononuclear cell (PBMC) model was employed to assess the effects of aripiprazole on cytokine profiles. Cells were stimulated with microparticles coated with antibodies to CD3 and CD28 surface markers. To investigate the roles of D1 and D2 dopamine receptors (D1DR and D2DR) in the mechanism of action of aripiprazole, PBMCs were stimulated in the presence of aripiprazole alone and in combination with specific antagonists: SCH23390 for D1DR and sulpiride for D2DR. Concentrations of IL-17 and IFN-γ in culture supernatants were measured using an enzyme-linked immunosorbent assay. Results. In patients with schizophrenia, the induced production of both IL-17 and IFN-γ by PBMC was significantly lower than in the healthy donor group. Aripiprazole exhibited a dose-dependent suppressive effect on cytokine secretion in both groups. Blockade of D1DR enhanced the inhibitory effect of aripiprazole, whereas blockade of D2DR diminished it. Isolated blockade of D1DR, in the absence of aripiprazole, inhibited cytokine production by stimulated PBMCs in both groups, while isolated blockade of D2DR had no significant effect. Conclusion. Aripiprazole may exert anti-inflammatory effects in schizophrenia by inhibiting the secretion of pro-inflammatory cytokines by T cells. This effect is likely mediated through D2DR activation.
- Open Access
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 26-32
The role of noradrenaline in regulating the interaction between CD14+ monocytes and CD4+ T cells in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects young people. It has been established that CD14+ monocytes and T-helpers (CD4+ T cells) play an important role in both the development and maintenance of autoimmune neuroinflammation in MS. Noradrenaline is one of the key neurotransmitters of the CNS, which, along with regulating neuropsychological functions, also participates in the modulation of cells of the innate and adaptive immune response.Objective: to investigate the effect of noradrenaline on CD14+ monocyte-induced activation of CD4+ T cells in patients with relapsing-remitting MS.Materials and methods. A comprehensive clinical and immunological examination was conducted on 12 patients with relapsing-remitting MS and 12 healthy donors. The effect of noradrenaline on the production of interleukin 6 (IL6) and IL1 β by CD14+ monocytes, which are necessary for the differentiation of Th17 cells, as well as on the activation of the PKA–CREB signalling pathway in CD14+ monocytes, was assessed. In addition, the effect of noradrenaline on the ability of CD14+ monocytes to induce the production of IL17 and interferon γ by autologous CD4+ T cells was evaluated.Results. Noradrenaline suppressed cytokine production by CD14+ monocytes in both groups, as well as activation of the PKA–CREB signalling pathway in the group of healthy donors. Noradrenaline also suppressed the ability of CD14+ monocytes to induce IL17 production by autologous CD4+ T cells in both groups.Conclusion. Preliminary data indicate that noradrenaline has an anti-inflammatory effect in MS, which may be mediated by its influence on the function of CD14+ monocytes.
- 23 August 2025
- Published by IMA Press, LLC in Neurology, Neuropsychiatry, Psychosomatics
- Vol. 17 (4) , 26-32
Open AccessThe role of noradrenaline in regulating the interaction between CD14+ monocytes and CD4+ T cells in multiple sclerosis
Multiple sclerosis (MS) is an autoimmune demyelinating and neurodegenerative disease of the central nervous system (CNS) that affects young people. It has been established that CD14+ monocytes and T-helpers (CD4+ T cells) play an important role in both the development and maintenance of autoimmune neuroinflammation in MS. Noradrenaline is one of the key neurotransmitters of the CNS, which, along with regulating neuropsychological functions, also participates in the modulation of cells of the innate and adaptive immune response.Objective: to investigate the effect of noradrenaline on CD14+ monocyte-induced activation of CD4+ T cells in patients with relapsing-remitting MS.Materials and methods. A comprehensive clinical and immunological examination was conducted on 12 patients with relapsing-remitting MS and 12 healthy donors. The effect of noradrenaline on the production of interleukin 6 (IL6) and IL1 β by CD14+ monocytes, which are necessary for the differentiation of Th17 cells, as well as on the activation of the PKA–CREB signalling pathway in CD14+ monocytes, was assessed. In addition, the effect of noradrenaline on the ability of CD14+ monocytes to induce the production of IL17 and interferon γ by autologous CD4+ T cells was evaluated.Results. Noradrenaline suppressed cytokine production by CD14+ monocytes in both groups, as well as activation of the PKA–CREB signalling pathway in the group of healthy donors. Noradrenaline also suppressed the ability of CD14+ monocytes to induce IL17 production by autologous CD4+ T cells in both groups.Conclusion. Preliminary data indicate that noradrenaline has an anti-inflammatory effect in MS, which may be mediated by its influence on the function of CD14+ monocytes.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 23-27
The role of monocytes in the immunopathogenesis of multiple sclerosis
Objective. To systematize data on the role of monocytes in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Material and methods. Forty-six scientific publications (1990—2024) on the role of monocytes in the pathogenesis of EAE and MS were analyzed. Results. Monocytes have been found to play an essential role in both the occurrence and persistence of autoimmune neuroinflammation. They penetrate the central nervous system (CNS) through the blood-brain barrier, produce pro-inflammatory cytokines, differentiate into macrophages/dendritic cells, and activate CD4+ T-cells. The change in both quantitative and functional characteristics of monocytes in MS is described. Conclusion. Monocytes are involved in all stages of the immunopathogenesis of EAE and MS and largely mediate autoimmune demyelination in the CNS. Therefore, they can be considered a potential therapeutic target for MS.
- 8 August 2025
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 125 (7) , 23-27
The role of monocytes in the immunopathogenesis of multiple sclerosis
Objective. To systematize data on the role of monocytes in the pathogenesis of multiple sclerosis (MS) and experimental autoimmune encephalomyelitis (EAE). Material and methods. Forty-six scientific publications (1990—2024) on the role of monocytes in the pathogenesis of EAE and MS were analyzed. Results. Monocytes have been found to play an essential role in both the occurrence and persistence of autoimmune neuroinflammation. They penetrate the central nervous system (CNS) through the blood-brain barrier, produce pro-inflammatory cytokines, differentiate into macrophages/dendritic cells, and activate CD4+ T-cells. The change in both quantitative and functional characteristics of monocytes in MS is described. Conclusion. Monocytes are involved in all stages of the immunopathogenesis of EAE and MS and largely mediate autoimmune demyelination in the CNS. Therefore, they can be considered a potential therapeutic target for MS.
- Open Access
- 23 March 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (1) , 56-63
Schizophrenia and neuroinflammation: Pathogenetic and therapeutic aspects
Introduction. Schizophrenia is a complex mental disorder with heterogeneous symptoms, including psychotic, negative, cognitive, affective, and psychomotor symptoms. Although the pathogenesis of schizophrenia is mainly associated with neurotransmitter imbalance, recent studies have suggested the importance of neuroinflammation in the pathogenesis of this disease.Objective. To study the involvement of neuroinflammation in the pathogenesis of schizophrenia and a prognostic assessment of the potential anti-inflammatory effect of antipsychotic medications.Discussion. Current data indicate a significant role of neuroinflammation in the development and course of schizophrenia. At the initial stages of its development, the number of lymphocytes and the level of some proinflammatory cytokines (IL-1, IL-6, TNF-α, IL-1β) increase, which can be decreased by antipsychotic therapy. Studies involving experimental models of maternal immune activation (MIA) and data obtained by immunohistochemical and PET studies confirm an abnormal activation of microglia, indicating the involvement of innate immune cells. Adaptive immune response cells can also play a significant role in the development of neuroinflammation in schizophrenia. Thus, an increased level of Th17 cells and an increase in the production of proinflammatory cytokines, correlating with the disease severity, were revealed. The role of neurotransmitters in modulating the immune-inflammatory response is discussed. Available data suggest that the participation of dopamine in the schizophrenia pathogenesis can be mediated by its immunomodulatory effect. The role of neuroinflammation in schizophrenia is also indicated by the clinical effectiveness of anti-inflammatory treatment in this disease. On the other hand, the immunomodulatory effect of antipsychotics has been established, which, at least in part, may mediate their clinical effectiveness in schizophrenia.Conclusions. Given the importance of neuroinflammation in the schizophrenia pathogenesis, further studies into both the anti-inflammatory properties of antipsychotics and the effects of anti-inflammatory drugs in schizophrenia are promising in order to further optimize the treatment of this disease.
- 23 March 2025
- Published by Federal Medical Biological Agency in Extreme Medicine
- Vol. 27 (1) , 56-63
Open AccessSchizophrenia and neuroinflammation: Pathogenetic and therapeutic aspects
Introduction. Schizophrenia is a complex mental disorder with heterogeneous symptoms, including psychotic, negative, cognitive, affective, and psychomotor symptoms. Although the pathogenesis of schizophrenia is mainly associated with neurotransmitter imbalance, recent studies have suggested the importance of neuroinflammation in the pathogenesis of this disease.Objective. To study the involvement of neuroinflammation in the pathogenesis of schizophrenia and a prognostic assessment of the potential anti-inflammatory effect of antipsychotic medications.Discussion. Current data indicate a significant role of neuroinflammation in the development and course of schizophrenia. At the initial stages of its development, the number of lymphocytes and the level of some proinflammatory cytokines (IL-1, IL-6, TNF-α, IL-1β) increase, which can be decreased by antipsychotic therapy. Studies involving experimental models of maternal immune activation (MIA) and data obtained by immunohistochemical and PET studies confirm an abnormal activation of microglia, indicating the involvement of innate immune cells. Adaptive immune response cells can also play a significant role in the development of neuroinflammation in schizophrenia. Thus, an increased level of Th17 cells and an increase in the production of proinflammatory cytokines, correlating with the disease severity, were revealed. The role of neurotransmitters in modulating the immune-inflammatory response is discussed. Available data suggest that the participation of dopamine in the schizophrenia pathogenesis can be mediated by its immunomodulatory effect. The role of neuroinflammation in schizophrenia is also indicated by the clinical effectiveness of anti-inflammatory treatment in this disease. On the other hand, the immunomodulatory effect of antipsychotics has been established, which, at least in part, may mediate their clinical effectiveness in schizophrenia.Conclusions. Given the importance of neuroinflammation in the schizophrenia pathogenesis, further studies into both the anti-inflammatory properties of antipsychotics and the effects of anti-inflammatory drugs in schizophrenia are promising in order to further optimize the treatment of this disease.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 79-84
The role of dopamine receptors in the modulation of mononuclear phagocytes in multiple sclerosis
Objective. To investigate the role of dopamine receptor D1DR and D2DR in the production of cytokines interleukin-6 (IL-6) and IL-1β by monocytes and macrophages in patients with relapsing-remitting multiple sclerosis (MS). Material and methods. Ten patients with relapsing-remitting MS and 10 healthy subjects were examined. The level of IL-6 and IL-1β production was assessed in culture supernatants obtained from CD14+ monocytes or macrophages stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS). To study the role of dopamine receptors in the regulation of CD14+ monocytes or macrophages, samples of cells were incubated in the presence of specific D1DR or D2DR antagonists, after which IFN-γ/LPS were added to the cultures. Levels of cytokines in culture supernatants were measured by enzyme-linked immunosorbent assay. Results. The production of IL-6 and IL-1β by CD14+ monocytes and macrophages was comparable between the groups. Blockade of D1DR suppressed cytokine production by CD14+ monocytes and macrophages in both groups. In contrast, blockade of D2DR increased the production of cytokines by CD14+ monocytes and did not affect cytokine production by macrophages in both groups. Conclusions. Targeting of dopaminergic receptors could be considered as an additional mechanism of immunomodulation in MS with both pro- and anti-inflammatory effects on cells of the innate immune system.
- 23 April 2024
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 124 (7) , 79-84
The role of dopamine receptors in the modulation of mononuclear phagocytes in multiple sclerosis
Objective. To investigate the role of dopamine receptor D1DR and D2DR in the production of cytokines interleukin-6 (IL-6) and IL-1β by monocytes and macrophages in patients with relapsing-remitting multiple sclerosis (MS). Material and methods. Ten patients with relapsing-remitting MS and 10 healthy subjects were examined. The level of IL-6 and IL-1β production was assessed in culture supernatants obtained from CD14+ monocytes or macrophages stimulated with interferon-γ (IFN-γ) and lipopolysaccharide (LPS). To study the role of dopamine receptors in the regulation of CD14+ monocytes or macrophages, samples of cells were incubated in the presence of specific D1DR or D2DR antagonists, after which IFN-γ/LPS were added to the cultures. Levels of cytokines in culture supernatants were measured by enzyme-linked immunosorbent assay. Results. The production of IL-6 and IL-1β by CD14+ monocytes and macrophages was comparable between the groups. Blockade of D1DR suppressed cytokine production by CD14+ monocytes and macrophages in both groups. In contrast, blockade of D2DR increased the production of cytokines by CD14+ monocytes and did not affect cytokine production by macrophages in both groups. Conclusions. Targeting of dopaminergic receptors could be considered as an additional mechanism of immunomodulation in MS with both pro- and anti-inflammatory effects on cells of the innate immune system.
- 10 August 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (7) , 65-71
The influence of fluoxetine on neuroimmune interaction in multiple sclerosis
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить влияние флуоксетина на патогенетически значимый при рассеянном склерозе (РС) Th17- и Th1-иммунный ответ. МАТЕРИАЛ И МЕТОДЫ Обследованы 10 больных ремиттирующим РС и 10 здоровых доноров. Th17- и Th1-иммунный ответ оценивали по продукции цитокинов интерлейкина-17 (ИЛ-17) и интерферона-γ (ИФН-γ) CD4+ T-клетками, активированными макрофагами или микрочастицами, покрытыми анти-CD3/CD28-антителами. Для оценки влияния флуоксетина на индуцируемый макрофагами Th17- и Th1-иммунный ответ макрофаги преинкубировали в присутствии флуоксетина и проводили ко-культивирование с аутологичными CD4+ T-клетками. В случае стимуляции CD4+ T-клеток анти-CD3/CD28-микрочастицами флуоксетин вносили непосредственно к T-хелперам перед внесением микрочастиц. Кроме того, оценивалось влияние флуоксетина на продукцию макрофагами факторов дифференцирования Th17-клеток — цитокинов ИЛ-6 и ИЛ-1β. Уровни цитокинов в супернатантах клеточной культуры измеряли методом иммуноферментного анализа. РЕЗУЛЬТАТЫ Продукция ИЛ-17 и ИФН-γ CD4+ T-клетками, стимулированными макрофагами или анти-CD3/CD28-микрочастицами, была сопоставима между группами. Продукция ИЛ-6 и ИЛ-1β макрофагами больных РС и здоровых доноров также была сопоставима. Флуоксетин подавлял выработку ИЛ-17 и ИФН-γ анти-CD3/CD28-стимулированными CD4+ T-клетками в обеих группах. Кроме того, флуоксетин подавлял продукцию ИЛ-6 и ИЛ-1β макрофагами, а также их способность индуцировать продукцию ИЛ-17 и ИФН-γ CD4+ T-клетками в обеих группах. ЗАКЛЮЧЕНИЕ Флуоксетин может оказывать противовоспалительное влияние при РС, оказывая ингибирующий эффект непосредственно на Th17- и Th1-клетки, а также на индуцируемый макрофагами Th17- и Th1-иммунный ответ.
- 10 August 2023
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 123 (7) , 65-71
The influence of fluoxetine on neuroimmune interaction in multiple sclerosis
ЦЕЛЬ ИССЛЕДОВАНИЯ Изучить влияние флуоксетина на патогенетически значимый при рассеянном склерозе (РС) Th17- и Th1-иммунный ответ. МАТЕРИАЛ И МЕТОДЫ Обследованы 10 больных ремиттирующим РС и 10 здоровых доноров. Th17- и Th1-иммунный ответ оценивали по продукции цитокинов интерлейкина-17 (ИЛ-17) и интерферона-γ (ИФН-γ) CD4+ T-клетками, активированными макрофагами или микрочастицами, покрытыми анти-CD3/CD28-антителами. Для оценки влияния флуоксетина на индуцируемый макрофагами Th17- и Th1-иммунный ответ макрофаги преинкубировали в присутствии флуоксетина и проводили ко-культивирование с аутологичными CD4+ T-клетками. В случае стимуляции CD4+ T-клеток анти-CD3/CD28-микрочастицами флуоксетин вносили непосредственно к T-хелперам перед внесением микрочастиц. Кроме того, оценивалось влияние флуоксетина на продукцию макрофагами факторов дифференцирования Th17-клеток — цитокинов ИЛ-6 и ИЛ-1β. Уровни цитокинов в супернатантах клеточной культуры измеряли методом иммуноферментного анализа. РЕЗУЛЬТАТЫ Продукция ИЛ-17 и ИФН-γ CD4+ T-клетками, стимулированными макрофагами или анти-CD3/CD28-микрочастицами, была сопоставима между группами. Продукция ИЛ-6 и ИЛ-1β макрофагами больных РС и здоровых доноров также была сопоставима. Флуоксетин подавлял выработку ИЛ-17 и ИФН-γ анти-CD3/CD28-стимулированными CD4+ T-клетками в обеих группах. Кроме того, флуоксетин подавлял продукцию ИЛ-6 и ИЛ-1β макрофагами, а также их способность индуцировать продукцию ИЛ-17 и ИФН-γ CD4+ T-клетками в обеих группах. ЗАКЛЮЧЕНИЕ Флуоксетин может оказывать противовоспалительное влияние при РС, оказывая ингибирующий эффект непосредственно на Th17- и Th1-клетки, а также на индуцируемый макрофагами Th17- и Th1-иммунный ответ.
- Open Access
- 8 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 668
The Dual Role of the β2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis
Norepinephrine is a neurotransmitter that also has an immunomodulatory effect and is involved in multiple sclerosis (MS) pathogenesis. This study aimed to clarify the role of the β2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-γ (IFN-γ) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or β2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA. Norepinephrine suppressed IL-17 and IFN-γ production by the anti-CD3/anti-CD28-microbead-stimulated CD4+ T cells in both groups. Blockade of the β2-adrenoreceptor with the specific antagonist ICI 118.551 enhanced norepinephrine-mediated IL-17 suppression but decreased its inhibitory effect on IFN-γ production in MS patients. In contrast, the β2-adrenoreceptor agonist formoterol did not influence norepinephrine’s inhibitory effect on cytokine production in both groups. The blockade of the β2-adrenoreceptor, even in the absence of exogenous norepinephrine, suppressed IL-17 production but did not influence IFN-γ production in both groups. Conversely, β2-adrenoreceptor activation by formoterol decreased IFN-γ production and did not affect IL-17 production in both groups. These data illustrate the inhibitory effect of norepinephrine on IL-17 and IFN-γ production by CD4+ T cells in MS. The inhibitory effect of norepinephrine on IFN-γ production by CD4+ T cells in MS could be mediated via β2-adrenoreceptor activation.
- 8 January 2022
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 23 (2) , 668
Open AccessThe Dual Role of the β2-Adrenoreceptor in the Modulation of IL-17 and IFN-γ Production by T Cells in Multiple Sclerosis
Norepinephrine is a neurotransmitter that also has an immunomodulatory effect and is involved in multiple sclerosis (MS) pathogenesis. This study aimed to clarify the role of the β2-adrenoreceptor in the norepinephrine-mediated modulation of interleukin-17 (IL-17) and interferon-γ (IFN-γ) production, which play a critical pathogenetic role in MS. CD4+ T cells obtained from twenty-five relapsing-remitting MS patients and sixteen healthy subjects were cultured ex vivo with norepinephrine and/or β2-adrenoreceptor antagonist or agonist, followed by a cytokine production analysis using ELISA. Norepinephrine suppressed IL-17 and IFN-γ production by the anti-CD3/anti-CD28-microbead-stimulated CD4+ T cells in both groups. Blockade of the β2-adrenoreceptor with the specific antagonist ICI 118.551 enhanced norepinephrine-mediated IL-17 suppression but decreased its inhibitory effect on IFN-γ production in MS patients. In contrast, the β2-adrenoreceptor agonist formoterol did not influence norepinephrine’s inhibitory effect on cytokine production in both groups. The blockade of the β2-adrenoreceptor, even in the absence of exogenous norepinephrine, suppressed IL-17 production but did not influence IFN-γ production in both groups. Conversely, β2-adrenoreceptor activation by formoterol decreased IFN-γ production and did not affect IL-17 production in both groups. These data illustrate the inhibitory effect of norepinephrine on IL-17 and IFN-γ production by CD4+ T cells in MS. The inhibitory effect of norepinephrine on IFN-γ production by CD4+ T cells in MS could be mediated via β2-adrenoreceptor activation.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (5) , 51-56
The role of macrophages in the development of neuroinflammation in multiple sclerosis
Рассеянный склероз (РС) — хроническое демиелинизирующиее и нейродегенеративное заболевание центральной нервной системы (ЦНС) с аутоиммунным механизмом развития. Известно, что наряду с T- и B-лимфоцитами клетки врожденной иммунной системы также играют существенную роль в патогенезе РС. Макрофаги занимают центральное место в функционировании врожденной системы иммунного ответа и в зависимости от фенотипа обладают как про-, так и противовоспалительными свойствами. В ЦНС резидентные макрофаги формируют микроглию, способную презентировать антигены и продуцировать цитокины и в зависимости от активационного статуса участвовать как в развитии аутоиммунного воспаления, так и в поддержании иммунологической толерантности. В коротком сообщении представлены данные об участии макрофагов в патогенезе экспериментального аутоиммунного энцефаломиелита и РС. Обсуждаются современные методы модуляции функций макрофагов с целью терапии РС.
- 1 January 2022
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 122 (5) , 51-56
The role of macrophages in the development of neuroinflammation in multiple sclerosis
Рассеянный склероз (РС) — хроническое демиелинизирующиее и нейродегенеративное заболевание центральной нервной системы (ЦНС) с аутоиммунным механизмом развития. Известно, что наряду с T- и B-лимфоцитами клетки врожденной иммунной системы также играют существенную роль в патогенезе РС. Макрофаги занимают центральное место в функционировании врожденной системы иммунного ответа и в зависимости от фенотипа обладают как про-, так и противовоспалительными свойствами. В ЦНС резидентные макрофаги формируют микроглию, способную презентировать антигены и продуцировать цитокины и в зависимости от активационного статуса участвовать как в развитии аутоиммунного воспаления, так и в поддержании иммунологической толерантности. В коротком сообщении представлены данные об участии макрофагов в патогенезе экспериментального аутоиммунного энцефаломиелита и РС. Обсуждаются современные методы модуляции функций макрофагов с целью терапии РС.
- Open Access
- 14 April 2020
- Published by MDPI AG in Brain Sciences
- Vol. 10 (4) , 234
Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut–brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated.
- 14 April 2020
- Published by MDPI AG in Brain Sciences
- Vol. 10 (4) , 234
Open AccessMicrobiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know
An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut–brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated.
- 1 January 2020
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 120 (7) , 67-72
The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro
Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS). 5 patients with relapsing-remitting MS and five healthy subjects were examined. Levels of IL-6 and IL-1β were measured by ELISA in culture supernatants obtained from lipopolysaccharide stimulated dendritic cells. To assess the effect of fluoxetine on cytokine production, dendritic cells were stimulated in the presence of fluoxetine and antagonists of 5-HT1A-, 5-HT2A-, 5-HT2B-receptors or agonist of 5-HT2B-receptors. Cytokine production by dendritic cells was comparable in both groups. Fluoxetine suppressed IL-6 and IL-1β production in both groups. Blockade of 5-HT2B-receptors with specific antagonist RS 127445 reduced the inhibitory effect of fluoxetine on IL-1β production in both groups and IL-6 production in healthy subjects. In contrast, activation of 5-HT2B-receptors by specific agonist BW 723C86 increased the inhibitory effect of fluoxetine on IL-6 production by dendritic cells in both groups, but did not affect on IL-1β production. These data suggest an anti-inflammatory effect of fluoxetine in MS by modulating pro-inflammatory cytokines production by dendritic cells. This effect could be mediate by activation of 5-HT2B-receptors.
- 1 January 2020
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 120 (7) , 67-72
The influence of fluoxetine on interleukin-6 and interleukin-1β production by dendritic cells in multiple sclerosis in vitro
Was to evaluate the effect of selective serotonin reuptake inhibitor fluoxetine on the production of cytokines interleukin-6 (IL-6) and interleukin-1β (IL-1β) by dendritic cells in multiple sclerosis (MS). 5 patients with relapsing-remitting MS and five healthy subjects were examined. Levels of IL-6 and IL-1β were measured by ELISA in culture supernatants obtained from lipopolysaccharide stimulated dendritic cells. To assess the effect of fluoxetine on cytokine production, dendritic cells were stimulated in the presence of fluoxetine and antagonists of 5-HT1A-, 5-HT2A-, 5-HT2B-receptors or agonist of 5-HT2B-receptors. Cytokine production by dendritic cells was comparable in both groups. Fluoxetine suppressed IL-6 and IL-1β production in both groups. Blockade of 5-HT2B-receptors with specific antagonist RS 127445 reduced the inhibitory effect of fluoxetine on IL-1β production in both groups and IL-6 production in healthy subjects. In contrast, activation of 5-HT2B-receptors by specific agonist BW 723C86 increased the inhibitory effect of fluoxetine on IL-6 production by dendritic cells in both groups, but did not affect on IL-1β production. These data suggest an anti-inflammatory effect of fluoxetine in MS by modulating pro-inflammatory cytokines production by dendritic cells. This effect could be mediate by activation of 5-HT2B-receptors.